Skip to content
MarketScale
‹ Back to Industries

Sciences

The Great Texas Freeze of 2021 is Still Having an Impact on Trees. Here’s The Science Behind It.

The Great Texas Freeze The Great Texas Freeze of 2021 had varied negative consequences on the region, from actual fatalities, to damage to infrastructure and utilities. It’s not only still being felt, but often missed in tackling the lingering effects of weather anomalies: The impact on Texas’ trees. For example, East Texas pine trees face…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · BarkBudding SeasonForest ManagementIps Engraver Beetles
Share

Key takeaways

01

The Great Texas Freeze The Great Texas Freeze of 2021 had varied negative consequences on the region, from actual fatalities, to damage to infrastructure and utilities.

02

It’s not only still being felt, but often missed in tackling the lingering effects of weather anomalies: The impact on Texas’ trees.

03

For example, East Texas pine trees face…

The Great Texas Freeze

The Great Texas Freeze of 2021 had varied negative consequences on the region, from actual fatalities, to damage to infrastructure and utilities. It’s not only still being felt, but often missed in tackling the lingering effects of weather anomalies: The impact on Texas’ trees. For example, East Texas pine trees face a lingering threat from the Great Texas Freeze of 2021 in the form of Ips engraver beetles. The severely stressed trees, weakened by the freeze, are now vulnerable to these beetles that attack both healthy and stressed pines.

It’s important to recognize that trees are influenced by genetic predispositions and regional differences. This helps us better understand the complex interplay between environmental factors and tree health. The damage from the freeze on trees varied among tree species and individual trees, with some being more susceptible to harm due to breaking dormancy early, and trees from different regions, such as North Carolina and Louisiana, can exhibit unique responses to the same stressors. Professionals at the Treenewal Team, including VP of Operations Wesley Rivers, Southern Botanical Pro David Brantley, and Cleanscapes Pro James Theiss, delve deep into the impacts of the recent freeze on trees, touching on genetic predispositions, regional differences, and the need for proper care.

Treenewal Team’s Thoughts:

Wesley Rivers

“But the freeze was devastating to a lot of them. A lot of them looked like nothing happened, and a lot of them got completely killed. And I think the variability there is due to genetic differences. Trees that were breaking dormancy early were absorbing water. Water crystallizes and freezes inside the vascular tissue and ruptures vessels and breaks cell walls. This just devastates the interior of the plant. So, some trees that just were genetically predisposed to be early got really hurt. The timing of the freeze was a big problem because it was late. By mid-February, we’re normally warming up around here; trees had been exposed to 70-plus-degree weather the week before. The days are getting longer. All these things are triggering these trees to start getting active.” – Wesley Rivers, VP of Operations, TreeNewal

David Brantley

“There are live oak trees that spanned from Big Bend all the way up through the United States, and each genetic in that seed, in that tree, has a different time when it breaks bud, has a different way it responds to things like that. So if we’re getting trees from North Carolina, it’s a different tree than you’re getting from Louisiana even though it is a live oak…” – David Brantley, Southern Botanical, TreeNewal

James Theiss

“He’s saying about the freeze damage. You don’t want to strap the bark on, we’ve seen that…. Bark that’s broken and separating, it’s going to fall off. A lot of is popping off right now in trees that people didn’t even know what happened. And the thing around that, remember that trees make their own root soil. So just like Wes was talking, the ones in residential areas are not getting any leaf litter. That leaf litter is supposed to be under the tree. It degrades to go back into the soil, and feeds the tree. But we clean all of that up. We don’t give the trees any substance, they just have to use what’s available in the soil that we feed them.” – James Theiss, Cleanscapes, TreeNewal

Article written by Azam Saghir.

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences